This suggests that increased expression of miR-641 significantly contributes to erlotinib resistance development in NSCLC cells through activating ERK signaling by targeting NF1 and that inhibition of miR-641 may reverse the acquired resistance of NSCLC cells to erlotinib treatment [193]. The gene discussed is NF1; the disease is non-small cell lung carcinoma.